Application of the REVEAL risk score calculator 2.0 in the CHEST study.

Autor: Benza RL; Department of Medicine, Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: Raymond.Benza@osumc.edu., Farber HW; Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, USA., Frost AE; Department of Medicine, Research Institute and Institute of Academic Medicine, Houston Methodist, Houston, TX, USA., Ghofrani HA; University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany; Department of Medicine, Imperial College London, London, UK; Department of Pneumology, Kerckhoff-Klinik, Bad Nauheim, Germany., Corris PA; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK., Lambelet M; Chrestos Concept GmbH & Co. KG, Essen, Germany., Nikkho S; Global Clinical Development, Bayer AG, Berlin, Germany., Meier C; Global Medical Affairs, Bayer AG, Berlin, Germany., Hoeper MM; Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany.
Jazyk: angličtina
Zdroj: Respiratory medicine [Respir Med] 2022 Apr-May; Vol. 195, pp. 106783. Date of Electronic Publication: 2022 Mar 01.
DOI: 10.1016/j.rmed.2022.106783
Abstrakt: Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for risk assessment in patients with pulmonary arterial hypertension, has previously predicted outcomes in CTEPH. RRS 2.0 was developed to refine the RRS.
Methods: This post hoc analysis of the CHEST study (n = 237), which assessed riociguat in patients with inoperable and persistent/recurrent CTEPH, evaluated RRS 2.0 and its relationship with survival and clinical worsening-free survival (CWFS).
Results: At CHEST-1 Week 16, RRS 2.0 significantly improved and more patients moved into the low-risk stratum with riociguat versus placebo; these improvements were maintained at CHEST-2 Week 12. RRS 2.0 at CHEST-1 baseline and Week 16, and change in RRS 2.0 from CHEST-1 baseline to Week 16 were significant predictors of survival and CWFS in CHEST-2.
Conclusions: Our data suggest that RRS 2.0 may have utility in predicting outcomes and monitoring treatment response in patients with inoperable or persistent/recurrent CTEPH.
(Copyright © 2022. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: